Frazier Life Sciences Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001892134

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2025 · 47 positions · Total reported value $3.34B · Top-10 concentration 69.5% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 22.7% · 6 new · 1 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +20.6% · vs SPY +5.8% · Prev Value $3.89B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2025 13F filing, Frazier Life Sciences Management, L.P. disclosed 47 equity positions with a combined reported value of $3.34B. The filing implies a focused portfolio: its ten largest positions account for 69.5% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2025 were MIRM ($498.15M), NAMS ($475.00M), VRNA ($361.10M). By sector, the heaviest allocations are Health Care 85.5%, Materials 0.3%. Versus the prior quarter, allocation shifted toward Health Care (+3.1pp) and away from Other (-3.2pp).

Versus the prior quarter, Frazier Life Sciences Management, L.P. opened 6 new positions, trimmed 1 and fully exited 3, a turnover rate of 22.7% of positions. The portfolio's overlap with the prior quarter was 81% of names.

The largest new positions opened in Q3 2025 were ABVX ($32.12M), ACAD ($13.10M), ASMB ($11.68M).

Of the 3 positions fully exited versus the prior quarter, the largest were HLVX ($21.13M), CGON ($20.02M), COGT ($12.45M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2025)

  • ABVX ABIVAX SA · $32.12M
  • ACAD ACADIA PHARMACEUTICALS INC · $13.10M
  • ASMB ASSEMBLY BIOSCIENCES INC · $11.68M
  • ENGN ENGENE THERAPEUTICS INC · $7.90M

Fully Exited (vs previous quarter)

  • HLVX HILLEVAX INC · prev qtr: $21.13M
  • CGON CG ONCOLOGY INC · prev qtr: $20.02M
  • COGT COGENT BIOSCIENCES INC · prev qtr: $12.45M
  • ORIC ORIC PHARMACEUTICALS INC · prev qtr: $10.81M
  • ORKA ORUKA THERAPEUTICS INC · prev qtr: $6.54M
  • ELEV ELEVATION ONCOLOGY INC · prev qtr: $2.20M

Insider Transactions (Form 4)

Latest Frazier Life Sciences Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Frazier Life Sciences Management, L.P. is an SEC-registered 13F filer. As of Q2 2026 it reported 41 US equity positions with a combined value of $4.59B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 41 positions · $4.59B reported value (Q2 2026)
  • Top 10 holdings = 73.6% of reported value
  • Largest position: MIRM (MIRUM PHARMACEUTICALS INC) at 19.6%
  • Average position size: $112.00M

Sector Tilt

  • Health Care 99.8%
  • Materials 0.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 8 added, 1 reduced, 3 exited
  • 26 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 85.5%
Materials 0.3%
Other 14.3%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 6.80M $498.15M 14.93%
14.93%
Hold
2 16.70M $475.00M 14.23%
14.23%
Add
3 3.38M $361.10M 10.82%
10.82%
Hold
4 3.85M $199.73M 5.99%
5.99%
Add
5 9.87M $186.13M 5.58%
5.58%
Hold
6 12.47M $146.73M 4.40%
4.40%
Hold
7 688.46K $121.53M 3.64%
3.64%
Hold
8 4.57M $118.43M 3.55%
3.55%
Hold
9 6.65M $116.41M 3.49%
3.49%
Add
10 1.44M $95.06M 2.85%
2.85%
Reduce
11 10.26M $93.87M 2.81%
2.81%
Hold
12 1.17M $69.39M 2.08%
2.08%
Reduce
13 5.04M $61.39M 1.84%
1.84%
Add
14 1.63M $55.15M 1.65%
1.65%
Add
15 1.28M $51.37M 1.54%
1.54%
Hold
16 22.73M $49.55M 1.49%
1.49%
Hold
17 890.45K $48.94M 1.47%
1.47%
Add
18 997.46K $46.58M 1.40%
1.40%
Hold
19 722.40K $45.29M 1.36%
1.36%
Hold
20 11.46M $40.92M 1.23%
1.23%
Hold
21 2.72M $34.38M 1.03%
1.03%
Add
22 378.30K $32.12M 0.96%
0.96%
New
23 5.10M $31.52M 0.94%
0.94%
Hold
24 983.72K $29.59M 0.89%
0.89%
Hold
25 4.42M $29.38M 0.88%
0.88%
Hold
26 2.29M $27.96M 0.84%
0.84%
Add
27 625.00K $27.23M 0.82%
0.82%
Hold
28 133.33K $26.51M 0.79%
0.79%
Hold
29 700.65K $21.02M 0.63%
0.63%
Reduce
30 9.44M $19.45M 0.58%
0.58%
Hold
31 366.78K $17.41M 0.52%
0.52%
Hold
32 474.40K $17.09M 0.51%
0.51%
Hold
33 2.63M $16.15M 0.48%
0.48%
Add
34 1.95M $14.71M 0.44%
0.44%
Hold
35 384.78K $13.98M 0.42%
0.42%
Hold
36 613.84K $13.10M 0.39%
0.39%
New
37 1.41M $12.20M 0.36%
0.36%
Reduce
38 456.25K $11.68M 0.35%
0.35%
New
39 2.08M $9.41M 0.28%
0.28%
Add
40 392.09K $9.37M 0.28%
0.28%
Reduce
41 500.33K $8.56M 0.26%
0.26%
Hold
42 1.16M $7.90M 0.24%
0.24%
New
43 4.62M $7.54M 0.23%
0.23%
Hold
44 3.18M $5.34M 0.16%
0.16%
Hold
45 970.13K $5.03M 0.15%
0.15%
Hold
46 3.87M $4.80M 0.14%
0.14%
Hold
47 272.95K $3.25M 0.10%
0.10%
Reduce

FAQ

What did Frazier Life Sciences Management, L.P. buy in 2025-Q3?

In its 2025-Q3 13F filing, Frazier Life Sciences Management, L.P. reported 47 equity positions worth $3.34B in aggregate; its largest disclosed positions were MIRM ($498.15M), NAMS ($475.00M), VRNA ($361.10M).

How large is Frazier Life Sciences Management, L.P.'s portfolio?

Frazier Life Sciences Management, L.P. reported $3.34B of long equity holdings across 47 positions as of 2025-Q3. Top-10 holdings account for 69.5% of reported value.

What is Frazier Life Sciences Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/frazier-life-sciences-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →